<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467412</url>
  </required_header>
  <id_info>
    <org_study_id>FCS-002</org_study_id>
    <secondary_id>2017-003809-17</secondary_id>
    <nct_id>NCT03467412</nct_id>
  </id_info>
  <brief_title>To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Follicum AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bioskin GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Follicum AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was a multicentre, randomised, double-blind, placebo controlled phase 2 trial.&#xD;
&#xD;
      60 healthy bald male subjects diagnosed with alopecia, who are between 18 and 55 years old&#xD;
      and provide written informed consent were eligible for inclusion.&#xD;
&#xD;
      The trial period consisted of a screening period of up to 3 weeks followed by 12 weeks of&#xD;
      dosing, three times per week. Each subject received two doses of the five trial treatment&#xD;
      doses (placebo, 0.00625, 0.025, 0.050, and 0.100 μg respectively). The doses were given as&#xD;
      intradermal injections. On each volunteer, two treatment areas were placed on the head and&#xD;
      the two selected doses were allocated to the respective treatment areas according to the&#xD;
      randomisation scheme. The treatment areas were selected on the border between the bald&#xD;
      surface and the surface with hair.&#xD;
&#xD;
      The effect on hair growth was measured by the use of Trichoscan imaging and measuring method&#xD;
      at week 8 and 12. A baseline measaure was taken at day 0.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Actual">August 22, 2018</completion_date>
  <primary_completion_date type="Actual">August 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scalp Hair Density</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of total hair density (No. of hairs per cm&quot;2&quot;) on the scalp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Anagen Hairs (%)</measure>
    <time_frame>From baseline to after 12 weeks treatment</time_frame>
    <description>Change from baseline in proportion of anagen hairs (%) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proportion of Telogen Hairs (%)</measure>
    <time_frame>From baseline to after 12 weeks treatment</time_frame>
    <description>Change from baseline in proportion of telogen hairs (%) on the scalp after 12 weeks of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anagen Hair Density</measure>
    <time_frame>From baseline to after 12 weeks treatment</time_frame>
    <description>Change from baseline of anagen hair density (number of hairs per cm&quot;2&quot;) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Telogen Hair Density</measure>
    <time_frame>From baseline to after 12 weeks treatment</time_frame>
    <description>Change from baseline of telogen hair density (number of hairs per cm2) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Androgenic Alopecia</condition>
  <arm_group>
    <arm_group_label>0.00625 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.025 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.050 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.100 μg FOL-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 μl solution (placebo) injected intradermally three times per week for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOL-005</intervention_name>
    <description>intradermal injection</description>
    <arm_group_label>0.00625 μg FOL-005</arm_group_label>
    <arm_group_label>0.025 μg FOL-005</arm_group_label>
    <arm_group_label>0.050 μg FOL-005</arm_group_label>
    <arm_group_label>0.100 μg FOL-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intradermal injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male, aged 18-55 years&#xD;
&#xD;
          -  Androgenetic alopecia (AGA)) - Norwood/Hamilton grade 3V to 4/4a&#xD;
&#xD;
          -  Caucasian, skin type I - IV according to Fitzpatrick's classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any dermatological disorders of the scalp which might interfere with the application&#xD;
             of Investigational Medical Product or examination method, such as fungal or bacterial&#xD;
             infections, seborrheic dermatitis, psoriasis, eczema, folliculitis or scalp atrophy&#xD;
&#xD;
          -  Any skin pathology (e.g. scar, nevus) or general condition (e.g. uncontrolled thyroid&#xD;
             diseases) that in the investigator's opinion can interfere with the evaluation of the&#xD;
             treatment areas or requires topical or systemic therapy&#xD;
&#xD;
          -  History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen&#xD;
             effluvium or conditions other than androgenetic alopecia&#xD;
&#xD;
          -  Immunological disorders such as alopecia areata, and systemic lupus erythematosus and&#xD;
             other systemic known autoimmune disorders&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Coagulation deficiencies&#xD;
&#xD;
          -  Topical treatments for hair growth (minoxidil, anti-androgens or other agents known to&#xD;
             affect hair growth) in the last 6 months&#xD;
&#xD;
          -  Topical treatments of the scalp including corticosteroids, tacrolimus, retinoids in&#xD;
             the last 2 months or other treatments that may affect hair growth&#xD;
&#xD;
          -  Platelet rich plasma (PRP) treatment on scalp during the last 12 months&#xD;
&#xD;
          -  Systemic therapy using retinoids, cyclosporine within the last 3 months&#xD;
&#xD;
          -  Systemic treatment with beta blockers or corticosteroids, scalp procedures e.g.&#xD;
             surgery, laser, light, micro-needling within the last 6 months&#xD;
&#xD;
          -  Finasteride (e.g. Propecia®) or Dutasteride intake in the last 12 months, or any&#xD;
             systemic hair therapy medication in the last 12 months&#xD;
&#xD;
          -  History of any acute (e.g. acute infections) or chronic illness (e.g. psoriasis,&#xD;
             atopic dermatitis, porphyria) or known skin cancer that in the opinion of the&#xD;
             investigators might confound the results of the trial&#xD;
&#xD;
          -  History or clinical signs of keloids or hypertrophic scars&#xD;
&#xD;
          -  Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test at screening&#xD;
&#xD;
          -  Current or within 2 weeks prior to first dosing use of vasodilating drugs (e.g.&#xD;
             Pentoxifylline, nitroglycerine) or anticoagulating drugs (e.g. heparins, cumarins, new&#xD;
             oral anticoagulants, regular intake of acetylsalicylic acid)&#xD;
&#xD;
          -  Current or within 3 months prior to first dosing use of anti-inflammatory medication&#xD;
             (ibuprofen, paracetamol is permitted), corticosteroids (nose drops, eye drops and/or&#xD;
             inhalers are permitted) or immunosuppressive drugs taken for more than 2 consecutive&#xD;
             weeks&#xD;
&#xD;
          -  Hair transplantation at any time&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Blume-Peytavi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Dermatologie, Charité-Universitätsmedizin, Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioskin GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <results_first_submitted>September 30, 2020</results_first_submitted>
  <results_first_submitted_qc>December 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03467412/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Each subject received 2 dose strengths on 2 separate areas locally applied on the scalp. Thus, 120 treatment areas were defined in the trial but only 60 subjects participated. The number of participants in each arms are not unique subjects since each subject will appear in 2 arms. The total number of participants in the trial is 60.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.00625 μg FOL-005</title>
          <description>50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="P2">
          <title>0.025 μg FOL-005</title>
          <description>50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="P3">
          <title>0.050 μg FOL-005</title>
          <description>50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="P4">
          <title>0.100 μg FOL-005</title>
          <description>50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>50 μl solution (placebo) injected intradermally three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">Each unique subject will appear in 2 arms. Total sum of subjects is therefore120/2=60.</participants>
                <participants group_id="P2" count="25">Each unique subject will appear in 2 arms. Total sum of subjects is therefore120/2=60.</participants>
                <participants group_id="P3" count="25">Each unique subject will appear in 2 arms. Total sum of subjects is therefore120/2=60.</participants>
                <participants group_id="P4" count="25">Each unique subject will appear in 2 arms. Total sum of subjects is therefore120/2=60.</participants>
                <participants group_id="P5" count="20">Each unique subject will appear in 2 arms. Total sum of subjects is therefore120/2=60.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In total 60 subjects were recruited. However, each subject received 2 treatments which leads up to the total number of subjects appears to be twice as many, i.e. 120.&#xD;
Baseline characteristics only reported for the total number of recruited subjects, i.e. 60.</population>
      <group_list>
        <group group_id="B1">
          <title>Combined Baseline Presentation of All Randomised Patient Irrespective of Treatment</title>
          <description>In total 60 subjects were recruited. Each subject received 2 treatments in parallell on 2 different treatment areas. Baseline characteristics can therefore not be described for the individual treatment groups as they refer to treatment areas and not subjects. Hence, baseline characteristics are only reported for the total number of recruited subjects, i.e. 60.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Areas on the scalp</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Baseline values were only analysed for the whole study population of 60 subjects</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.91" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Areas on the scalp</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scalp Hair Density</title>
        <description>Change from baseline of total hair density (No. of hairs per cm&quot;2&quot;) on the scalp</description>
        <time_frame>12 weeks</time_frame>
        <population>Note: one subject receiving 0.00625 and 0.050 μg FOL-005 withdrew consent after treatment. Data for primary outcome were available and and consequently used. The nNumber of analysed subjects therefore exceeds number of completed subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>0.00625 μg FOL-005</title>
            <description>50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O2">
            <title>0.025 μg FOL-005</title>
            <description>50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O3">
            <title>0.050 μg FOL-005</title>
            <description>50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O4">
            <title>0.100 μg FOL-005</title>
            <description>50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>50 μl solution (placebo) injected intradermally three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Scalp Hair Density</title>
          <description>Change from baseline of total hair density (No. of hairs per cm&quot;2&quot;) on the scalp</description>
          <population>Note: one subject receiving 0.00625 and 0.050 μg FOL-005 withdrew consent after treatment. Data for primary outcome were available and and consequently used. The nNumber of analysed subjects therefore exceeds number of completed subjects.</population>
          <units>Change from baseline (No. of hairs/cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="14.75"/>
                    <measurement group_id="O2" value="2.58" spread="15.36"/>
                    <measurement group_id="O3" value="-4.10" spread="21.00"/>
                    <measurement group_id="O4" value="6.68" spread="22.24"/>
                    <measurement group_id="O5" value="5.60" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Anagen Hairs (%)</title>
        <description>Change from baseline in proportion of anagen hairs (%) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.)</description>
        <time_frame>From baseline to after 12 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.00625 μg FOL-005</title>
            <description>0.00625 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O2">
            <title>0.025 μg FOL-005</title>
            <description>0.025 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O3">
            <title>0.050 μg FOL-005</title>
            <description>0.050 μg FOL-005, solution. 50 μl injected intradermallys three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O4">
            <title>0.100 μg FOL-005</title>
            <description>0.100 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Anagen Hairs (%)</title>
          <description>Change from baseline in proportion of anagen hairs (%) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.)</description>
          <units>percentage of anagen hairs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="15.68"/>
                    <measurement group_id="O2" value="1.40" spread="11.43"/>
                    <measurement group_id="O3" value="-0.73" spread="14.23"/>
                    <measurement group_id="O4" value="3.18" spread="15.16"/>
                    <measurement group_id="O5" value="-3.08" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Proportion of Telogen Hairs (%)</title>
        <description>Change from baseline in proportion of telogen hairs (%) on the scalp after 12 weeks of</description>
        <time_frame>From baseline to after 12 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.00625 μg FOL-005</title>
            <description>0.00625 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O2">
            <title>0.025 μg FOL-005</title>
            <description>0.025 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O3">
            <title>0.050 μg FOL-005</title>
            <description>0.050 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O4">
            <title>0.100 μg FOL-005</title>
            <description>0.100 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proportion of Telogen Hairs (%)</title>
          <description>Change from baseline in proportion of telogen hairs (%) on the scalp after 12 weeks of</description>
          <units>percentage of telogen hairs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.49" spread="31.36"/>
                    <measurement group_id="O2" value="-0.05" spread="22.12"/>
                    <measurement group_id="O3" value="8.66" spread="34.71"/>
                    <measurement group_id="O4" value="2.21" spread="36.82"/>
                    <measurement group_id="O5" value="14.60" spread="25.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anagen Hair Density</title>
        <description>Change from baseline of anagen hair density (number of hairs per cm&quot;2&quot;) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.</description>
        <time_frame>From baseline to after 12 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.00625 μg FOL-005</title>
            <description>0.00625 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O2">
            <title>0.025 μg FOL-005</title>
            <description>0.025 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O3">
            <title>0.050 μg FOL-005</title>
            <description>0.050 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O4">
            <title>0.100 μg FOL-005</title>
            <description>0.100 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Anagen Hair Density</title>
          <description>Change from baseline of anagen hair density (number of hairs per cm&quot;2&quot;) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.</description>
          <units>number of hairs per cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="28.89"/>
                    <measurement group_id="O2" value="3.65" spread="21.77"/>
                    <measurement group_id="O3" value="-4.41" spread="24.85"/>
                    <measurement group_id="O4" value="5.79" spread="25.21"/>
                    <measurement group_id="O5" value="-2.31" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Telogen Hair Density</title>
        <description>Change from baseline of telogen hair density (number of hairs per cm2) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.)</description>
        <time_frame>From baseline to after 12 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.00625 μg FOL-005</title>
            <description>0.00625 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O2">
            <title>0.025 μg FOL-005</title>
            <description>0.025 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O3">
            <title>0.050 μg FOL-005</title>
            <description>0.050 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O4">
            <title>0.100 μg FOL-005</title>
            <description>0.100 μg FOL-005, solution. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo. 50 μl injected intradermally three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Telogen Hair Density</title>
          <description>Change from baseline of telogen hair density (number of hairs per cm2) on the scalp after 12 weeks of treatment. (Only data from subjects included in the PPS are reported.)</description>
          <units>number of hairs per cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="18.65"/>
                    <measurement group_id="O2" value="-1.06" spread="16.33"/>
                    <measurement group_id="O3" value="0.31" spread="16.39"/>
                    <measurement group_id="O4" value="0.89" spread="22.15"/>
                    <measurement group_id="O5" value="7.91" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Only local adverse events are reported by treatment arm. Systemic adverse events can not be reported by treatment since subjects received two treatments each. These have been reported in a separate group.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.00625 μg FOL-005</title>
          <description>0.00625 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="E2">
          <title>0.025 μg FOL-005</title>
          <description>0.025 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="E3">
          <title>0.050 μg FOL-005</title>
          <description>0.050 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="E4">
          <title>0.100 μg FOL-005</title>
          <description>0.100 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.&#xD;
FOL-005: intradermal injection</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo. 50 μl injected sub-cutaneous three times per week for 12 weeks.&#xD;
Placebo: intradermal injection</description>
        </group>
        <group group_id="E6">
          <title>Systemic Adverse Events</title>
          <description>The systemic (or non-local) AEs are reported for the whole group (60 subjects) only. these events can not be related to one dose strengthe since all subjects received more than one dose.&#xD;
Dose range for this group range from 0.0065 μg (subjects receiving a combination of the lowest dose and placebo) to 0.150 μg (subjects receiving a combination of the 2 highest doses)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site eczema</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application site pustules</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="10" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CEO Jan Alenfall</name_or_title>
      <organization>Follicum AB</organization>
      <phone>+46 (0)70 931 51 15</phone>
      <email>jan.alenfall@follicum.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

